Program
mezigdomide
Also written as “CC-92480”, “Mezigdomide” and “Cohort B1 & B2: KTX-1001+Mezigdomide”.
Its studies are mostly in Multiple Myeloma · Kidney Failure, Chronic, led by 2 companies.
Drug pageMezigdomide: every studyAll 22 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 113 open or running | phase 3since Aug 25, 2022 | Dec 1, 2017 | Jan 10, 2027phase 3 · NCT05519085 |
| K36 Therapeuticsits history only | 11 open or running | phase 1since Dec 1, 2022 | Dec 1, 2022 | Dec 31, 2027phase 1 · NCT05651932 |
- Named in Bristol-Myers Squibb’s own pipeline as
mezigdomide
, phase 4, as of Oct 29, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bristol-Myers Squibb only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Dec 1, 2017First study: phase 2 study in Multiple MyelomaFirst studyNCT03374085 · 200 enrolled · United States, Australia, Belgium and more
- Dec 17, 2018Phase 1 study in Healthy VolunteerNCT03803644 · 56 enrolled · United States
- Dec 24, 2019Phase 1 study in Healthy VolunteerNCT04211545 · 24 enrolled · United States
- Sep 21, 2020Phase 1 study in Healthy VolunteersNCT04560738 · 8 enrolled · United States
- Apr 7, 2021Phase 1 study in Healthy VolunteersNCT04839809 · 40 enrolled · United States
- Jul 28, 2021Named mezigdomideINNProposed as its International Nonproprietary Name in WHO's List 125 · before, CC-92480
- May 20, 2022Phase 1 study in Healthy VolunteersNCT05389722 · 24 enrolled · United States
- Aug 25, 2022Phase 3 study in RecurrenceNCT05519085 · 810 planned · United States, Argentina, Australia and more
- Sep 21, 2022Phase 3 study in RecurrenceNCT05552976 · 606 enrolled · United States, Argentina, Australia and more
- Jan 23, 2023Phase 1 study in Hepatic ImpairmentNCT05707390 · 32 enrolled · United States
- Mar 12, 2024Phase 1 study in Renal InsufficiencyNCT06318676 · 26 enrolled · United States
- May 16, 2025Phase 2 study in Multiple MyelomaNCT06988488 · 62 planned · United States, Canada, China and more
Ahead
- Jan 10, 2027Primary completion: phase 3 study in RecurrenceNCT05519085
- May 31, 2027Primary completion: phase 2 study in Multiple MyelomaNCT06988488
TargetBeta
“A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential immunomodulating and antineoplastic activities. Upon administration, mezigdomide specifically binds to cereblon (CRBN), thereby affecting the ubiquitin E3 ligase activity, and target…”NCIt, read by Claude
Other programs on CRBN
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Lenalidomiderule | Bristol-Myers Squibb | phase 4 | 109 |
| pomalidomiderule | Bristol-Myers Squibb | phase 4 | 51 |
| golcadomide | Bristol-Myers Squibb | phase 3 | 11 |
| Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506 | Bristol-Myers Squibb | phase 1 | 1 |
| HRS-3738 | Jiangsu HengRui Medicine | phase 1 | 1 |
Studies
All 11 Bristol-Myers Squibb leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06988488Multiple Myeloma · United States, Canada, China and more | 2 | Recruiting | May 31, 2027 | 62 |
| NCT06318676Renal Insufficiency · United States | 1 | Completed | Nov 15, 2024 | 26 |
| NCT05707390Hepatic Impairment · United States | 1 | Completed | Sep 13, 2023 | 32 |
| NCT05552976Recurrence · United States, Argentina, Australia and more | 3 | Active, not recruiting | Sep 28, 2026 | 606 |
| NCT05519085Recurrence · United States, Argentina, Australia and more | 3 | Recruiting | Jan 10, 2027 | 810 |
| NCT05389722Healthy Volunteers · United States | 1 | Completed | Nov 12, 2022 | 24 |
| NCT04839809Healthy Volunteers · United States | 1 | Completed | Oct 8, 2021 | 40 |
| NCT04560738Healthy Volunteers · United States | 1 | Completed | May 13, 2021 | 8 |
| NCT04211545Healthy Volunteer · United States | 1 | Completed | Dec 26, 2019 | 24 |
| NCT03803644Healthy Volunteer · United States | 1 | Completed | May 28, 2019 | 56 |
| NCT03374085Multiple Myeloma · United States, Australia, Belgium and more | 2 | Terminated | Aug 20, 2025 | 200 |
How it is read
Names in the registry
- “CC-92480”, 6 entries
- “Mezigdomide”, 4 entries
- “Cohort B1 & B2: KTX-1001+Mezigdomide”, 1 entry
- “mezigdomide”, 1 entry
- “[14C]-CC-92480”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 5 studies
- Kidney Failure, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.